Pharmalot By Ed Silverman Pharma donates big bucks to U.K. patient groups, but transparency found lacking
Pharmalot By Ed Silverman French medical schools don’t have policies to prevent conflicts with pharma
Pharmalot By Ed Silverman 21st Century Cures bill would weaken requirements for disclosing industry ties
Business By Sheila Kaplan From FDA expert to biotech insider: The drug industry thrives on the revolving door
Pharmalot By Ed Silverman Too many treatment guidelines are written by experts with financial conflicts, study finds